Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE-COV19 Study, September 2022 to March 2024
Routine COVID-19 boosters cut long COVID by more than half and reduce deaths by a quarter in vaccinated populations, keeping protection meaningful.
This large propensity-matched real-world study of 146,132 Germans shows that routine seasonal COVID-19 vaccination during the endemic phase reduces long COVID by 57%, COVID-19-related hospitalization by 59%, and all-cause mortality by 25%, with meaningful healthcare and indirect cost savings. The findings provide compelling population-scale evidence supporting continued national COVID-19 vaccination programs into the endemic era.
What the study was
- Study design
- Retrospective cohort study with 1:1 propensity score matching, German statutory health insurance data (Saxony + Thuringia), 2022-2024
- Population
- Adults ≥18 years vaccinated vs unvaccinated against COVID-19 (Sep-Nov 2023), n=146,132 matched pairs from 3+ million individuals
- Sample size
- 146132
- Category
- Prevention
- Maturity
- Validated
- Journal
- Euro Surveillance
Why it surfaced
Largest real-world study of endemic-phase COVID-19 vaccination with propensity matching (n=146,132). Long COVID reduction (57%) is particularly actionable given ongoing long COVID burden. Directly supports existing and future national immunization guidance during endemic SARS-CoV-2 circulation. BioNTech/Pfizer affiliated study — note potential COI for Phase 2 review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.